Rhonda Wideman

2005 Research Trainee Award, Senior Graduate Studentship

Engineering of islets to produce the anti-diabetic hormone GLP-1

More than 2 million Canadians and 135 million people worldwide have diabetes, a chronic medical condition characterized by a lack of insulin (Type 1), or insensitivity to insulin (Type 2), a blood sugar-lowering hormone. Type 1 diabetes can be treated by transplantation of islets, which contain the insulin-producing cells, to patients, but use of this therapy is limited by the huge volume of islets required to treat all Type 1 diabetes patients. As a result, most continue to rely on insulin injections to help control blood glucose levels. Glucagon-like peptide-1 (GLP-1) is produced in the intestine and has numerous anti-diabetic effects. Clinical trials are currently investigating GLP-1 as a treatment for Type 2 diabetes. Other recent studies show GLP-1 also enhances the growth of islet tissue. As a 2003 MSFHR Trainee, Rhonda Wideman investigated the effects of GLP-1 on the growth and survival of transplanted islets to determine if GLP-1 reduces the amount of islets needed to treat Type 1 diabetes in transplant recipients. Now in a PhD program, Rhonda is examining the therapeutic potential of engineering islets to produce GLP-1. She is investigating whether islets in which GLP-1 production has been induced will indeed survive and function better following transplantation. This would reduce the amount of islets necessary for a successful transplant and enhance post-transplant islet function. Ultimately, Rhonda hopes her studies will contribute to improved islet transplantation protocols, which are more effective and less reliant on limited supplies of donor islet tissue. Previously received 2003 MSFHR Trainee Award
Read Rhonda Wideman's 2003 Trainee profile

Back to 2005 Research Trainee Awards